Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydroxypropyl betadex - ZyVersa Therapeutics

Drug Profile

Hydroxypropyl betadex - ZyVersa Therapeutics

Alternative Names: 2-hydroxypropyl-β-cyclodextrin - ZyVersa Therapeutics; 2HPβCD - ZyVersa Therapeutics; Cholesterol Efflux Mediator™; HPβCD - ZyVersa Therapeutics; Hydroxypropyl beta cyclodextrin - ZyVersa Therapeutics; VAR 200; VAR 200-01; VAR 200-02; VAR 200-03; VAR 300; VAR 400

Latest Information Update: 21 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator L&F Research
  • Developer ZyVersa Therapeutics
  • Class Anti-inflammatories; Antidementias; Antivirals; Beta-Cyclodextrins; Ethers; Peripheral vasodilators; Urologics; Vascular disorder therapies
  • Mechanism of Action Binding agents; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic nephropathies; Focal segmental glomerulosclerosis; Hereditary nephritis

Most Recent Events

  • 21 Aug 2023 ZyVersa Therapeutics plans a phase IIa trial for Diabetic nephropathies in the first half of 2024
  • 06 Jun 2023 European Patent Office issued “Notice of Intention to Grant” ZyVersa’s patent application
  • 03 Apr 2023 ZyVersa Therapeutics plans a phase IIa trial for Focal segmental glomerulosclerosis in fourth quarter of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top